It's Not a Mystery, It's in the History: Multidisciplinary Management of Multiple Endocrine Neoplasia Type 1
Overview
Authors
Affiliations
Targeting MEN1-deficient tumors with DHODH inhibitor.
Zheng L J Natl Cancer Cent. 2024; 2(2):69.
PMID: 39034953 PMC: 11256604. DOI: 10.1016/j.jncc.2022.03.001.
Beyond the three P's: adrenal involvement in MEN1.
Clemente-Gutierrez U, Pieterman C, Lui M, Szabo Yamashita T, Tame-Elorduy A, Huang B Endocr Relat Cancer. 2023; 31(2).
PMID: 38108666 PMC: 10854230. DOI: 10.1530/ERC-23-0162.
Waguespack S Front Endocrinol (Lausanne). 2022; 13:1029041.
PMID: 36325452 PMC: 9618614. DOI: 10.3389/fendo.2022.1029041.
High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery.
Vargas S, AghaAmiri S, Ghosh S, Luciano M, Borbon L, Ear P Mol Pharm. 2022; 19(11):4241-4253.
PMID: 36174110 PMC: 9830638. DOI: 10.1021/acs.molpharmaceut.2c00583.